Reemergence of previous stroke-related deficits (or poststroke recrudescence [PSR]) is an underrecognized and inadequately characterized phenomenon.
T ransient worsening of poststroke neurologic deficits or reemergence of previous stroke-related deficits (or poststroke recrudescence [PSR] ) in the setting of toxic metabolic factors is a frequently encountered phenomenon that has not been adequately characterized. Anecdotal case reports and expert opinions have referred to PSR as anamnestic recall or recrudescence and have associated it with systemic infections and the use of sedative medications and anesthetic drugs. [1] [2] [3] A few clinical studies have demonstrated iatrogenic reemergence of previous stroke symptoms with the use of midazolam hydrochloride and fentanyl citrate. [4] [5] [6] [7] Rodent studies have provided preliminary mechanistic insights 3 ; however, the underlying biochemical and molecular mechanisms have yet to be elucidated. The baseline stroke phenotype and potential risk factors, event triggers, and the clinical characteristics, time course, and outcome of PSR have not been studied, to our knowledge. It can be difficult to distinguish PSR from mimics, such as acute stroke, transient ischemic attack (TIA), and seizure; however, accurate diagnosis is important given these conditions' diverse management. In this study, we describe the clinical-imaging phenotype, risk factors, and clinical outcome of PSR and propose diagnostic criteria.
Methods
This retrospective study design incorporated a crossover cohort study to identify triggers and a case-control study to identify risk factors. The Partners Human Research Committee approved the study and waived the informed consent requirement because the study was a retrospective medical record review without patient contact.
Patients with potential PSR were identified using the Massachusetts General Hospital Research Patient Data Repository (RPDR), an electronic database with natural-language processing query system that contains real-time patient information from numerous sources, including clinical encounters, billing data, radiologic images, and laboratory results. For this study, we queried the RPDR for the period January 1, 2000, to November 30, 2015, to identify patients coded with a primary or secondary diagnosis of "cerebrovascular disease" who underwent magnetic resonance (MR) imaging of the brain at least once and had any type of inpatient or outpatient clinician note or discharge summary in which the term recrudescence was stated. The MR imaging and clinical note were not restricted to the same encounter.
The RPDR query returned 3441 patients, from which a random sample of 1700 medical records (49.4%) was selected for detailed review. To identify the clinical note (and hence the encounter) containing recrudescence, we used a novel indigenous search engine called Queriable Patient Inference Dossier, which interrogates the specified patient's aggregate electronic health record for the relevant term. For each relevant encounter, we reviewed all clinical notes, laboratory results, MR imaging of the brain (including diffusion-weighted imaging [DWI]), and electroencephalographic results (if performed) to identify patients with PSR.
Criteria for PSR
Following are the preliminary diagnostic criteria for PSR: 
Features of PSR
The following data from the PSR admission were extracted: demographics, time interval since index stroke, tempo of onset, duration of recrudescence, presence of fever (body temperature ≥38.5°C), relative hypotension or hypertension in the judgment of the clinician, maximum National Institutes of Health Stroke Scale (NIHSS) score (score range: 0-42, with the higher scores indicating more severe focal deficits from stroke), relevant laboratory results (eg, complete blood cell count, blood glucose level, electrolyte levels, renal and liver function test results, blood cultures, inflammatory markers, urinalysis, chest radiography, and echocardiography), recent surgical operations, medications, brain and cerebrovascular imaging findings, and length of hospital stay. Episodes with possible recrudescence from a chronic asymptomatic (silent) stroke
Key Points
Question What are the clinical features, triggers, and risk factors of poststroke recrudescence?
Findings This crossover cohort and case-control study of 153 patients admitted for poststroke recrudescence found that it occurs approximately 4 years after the index stroke and is characterized by mild worsening of poststroke deficits that usually resolve within 1 day. Infection, hypotension, hyponatremia, insomnia or stress, and benzodiazepine use are important precipitants; recrudescence is more common in women, African American individuals, and patients with vascular risk factors, severe deficits, or infarcts affecting deep white matter tracts within the middle cerebral artery territory.
Meaning Results from this study should enable prompt diagnosis and help distinguish poststroke recrudescence from mimics.
were excluded. Baseline poststroke deficits, functional status, and estimated modified Rankin Scale (mRS) score (score range: 0-6, with the highest score indicating death) were extracted from medical records dated before the PSR admission.
Features of the Index Stroke
The following data were extracted: maximum NIHSS score, stroke type (ischemic or hemorrhagic), ischemic stroke etiology per the Trial of Org 10172 in Acute Stroke (TOAST) classification, 8 arterial territory (anterior, middle, or posterior cerebral; vertebrobasilar; or cerebellar branch arteries), stroke distribution (superficial or deep), stroke size (small, axial diameter 0 to 1.5 cm; medium, >1.5 to 3.0 cm; or large, >3.0 cm), and estimated time to resolution of deficits or plateau of stroke recovery. In patients with more than 1 previous stroke, the event with presenting symptoms consistent with the new recrudescence symptoms was selected.
Identification of PSR Triggers (Crossover Cohort Study)
We compared features of the PSR admissions with discrete hospitalizations when the patient did not experience recrudescence (ie, "control" admission group 
Results

Features of PSR
Diagnostic criteria were confirmed in 164 episodes (153 patients: 145 previous infarcts and 8 hypertensive brain hemorrhages). Eleven patients (7.2%), all with previous ischemic stroke, had more than 1 episode of PSR; triggers and symptoms were not identical for these recurrences. Of the 153 patients, the mean (SD) age was 67 (16) years, and 92 (60%) were women. All races were affected. A typical episode is depicted in Figure 1 .
We were unable to extract reliable information about the tempo of onset symptoms, however. In most cases, the onset appeared to be abrupt, similar to a stroke, and not gradual. The mean (SD) duration of the deficits, documented in 131 episodes, was 18.4 (20.4) hours with 91 episodes (69.5%) resolving on day 1, 23 (17.5%) on day 2, 8 (6.1%) on day 3, and 9 (6.9%) on day 4 or beyond. Resolution appeared to be gradual and usually correlated with removal or treatment of the presumed trigger. The mean (SD) interval from index stroke to recrudescence was 3.9 (0.6) years. A total of 111 episodes (67.6%) resulted in hospitalization, the rest discharged from the emergency department. The mean (SD) length of stay was 4.0 (4.9) days. Six patients (4.0%) received intravenous tissue plasminogen activator without hemorrhagic complications.
The mean (SD) NIHSS score immediately before the recrudescence spell was 2.8 (4.2). The maximum mean (SD) NIHSS score during recrudescence was 5.2 (4.6), and the mean (SD) change in NIHSS score was +2.5 (1.9). The range of NIHSS score worsening was 1 to 12 points, with a change of 4 or more in 28 episodes (17.0%). There was no significant difference in the NIHSS change score or event duration between recrudescence after ischemic and hemorrhagic stroke ( Figure 2 ). Subscale analysis of the NIHSS change score showed a wide variability in the distribution of neurologic deficits: Level of Consciousness, 10%; Gaze, 1%; Visual, 4%; Facial Palsy, 33%; Motor arm or leg, 49%; Limb Ataxia, 9%; Sensory, 26%; Language, 21%; Dysarthria, 26%; and Extinction-Inattention, 1%. Neurologic deficits were limited to a single subscale NIHSS item in 62 episodes (38%). These single-item deficits predominantly localized to the motor-sensory and language pathways. No patient had isolated gaze paresis, isolated hemianopia, or isolated neglect. Mental status appeared normal in 124 patients (75.6%); the rest had delirium or confusion, but none were comatose.
By definition, the electroencephalogram showed no active seizures in all 45 episodes (27.4%) where performed, and DWI showed no acute infarcts in 164 episodes (100%). Cerebral vascular imaging was performed in 158 episodes (96.3%).
New arterial pathology was ruled out with (in order of preference) head-neck computed tomography angiography in 64 episodes (40.5%), head-neck MR angiography in 84 (53.2%), headonly MR angiography in 5 (3.2%), and carotid duplex or transcranial Doppler ultrasonography in 5 (3.2%). However, vascular imaging showed more than 50% cerebral arterial stenosis or occlusion in 33 episodes (20.1%), which was judged by the clinicians to be stable since the previous stroke; in all such cases, the final clinical diagnosis was recrudescence and not TIA.
Triggers
The control group comprised 65 admissions before (16 [25%] ) and after (49 [75%]) the PSR encounter. There were no significant differences in demographic characteristics and index stroke features between the patients with recrudescence who did or did not (n = 99) have a control admission.
The mean (SD) interval between the PSR episode and the control episode was 671 (86) days. There was no significant difference between the PSR group and the control group in the mean (SD) length of stay (4.1 [4.7] days vs 4.1 [4.0] days; P = .98). The indications for the 65 control admissions included 13 trauma or falls; 7 back or neck pain; 3 orthopedic surgical procedures; 3 lower-limb vascular, 16 cardiorespiratory, 5 gastrointestinal, and 3 genitourinary tract conditions; 3 psychiatric events; 2 systemic infections; and 10 nonstroke neurologic symptoms, such as headache, vertigo, and seizure.
As shown in Table 1 , PSR episodes had a significantly higher frequency of infections, hypotension, and hyponatremia. Insomnia or stress, benzodiazepine use, and fever were more fre- Box-and-whisker plots show the distribution of NIHSS scores at the time of the index stroke, at poststroke baseline, and during recrudescence in patients with ischemic stroke and hemorrhagic stroke. There were no significant differences between NIHSS scores in the ischemic and hemorrhagic groups at the time of stroke onset ( quent but did not reach statistical significance. There were no significant differences in the use of antiseizure medications or stroke preventive medications, such as anticoagulants, or in admission international normalized ratio values among patients treated with warfarin sodium. All 8 hemorrhagic strokes were hypertensive in origin based on preexisting hypertension and location (5 thalamic and 3 putamen). Two strokes were small (confined to the thalamus), and the others were large and involved white matter tracts. 
Features of the Index Stroke
Research Original Investigation Recrudescence of Deficits After Stroke
The time to resolution of deficits or plateau of stroke recovery was adequately documented in 124 patients (85.5%). Recovery occurred within 1 week in 26 patients (21.0%), within 1 month in 55 (44.4%), and beyond 1 month in 43 (35%). The pre-PSR mean (SD) mRS score, estimated in all 145 patients, was 1.3 (1.2), with an mRS score of 0 in 39 patients (26.9%), 1 in 62 (42.8%), 2 in 15 (10.3%), 3 in 18 (12.4%), 4 in 9 (6.2%), and 5 in 2 (1.4%). Table 2 compares the 145 patients who had ischemic stroke and recrudescence with 1861 registry patients who had DWIconfirmed ischemic stroke but no recrudescence. A total of 25 patients (17%) had more than 1 previous stroke; for this comparison, we selected the previous ischemic stroke with symptoms similar to the recrudescence episode.
Risk Factors
The PSR group had substantially more women (90 [62.1%]), African American individuals (25 [17.2%]), and those who selfidentified as being of "other" races (19 [13.1%] ). Patients with recrudescence had higher frequencies of diabetes, dyslipidemia, smoking, and more severe neurologic deficits at the time of stroke. There were significantly more small-vessel infarcts and more strokes from other definite causes (eg, dissection) in the recrudescence group.
Discussion
Detailed analysis of this cohort of patients experiencing recordvalidated recrudescence of stroke symptoms provides new insights into this often-applied but poorly understood classification of transient neurologic symptoms. Our data show that PSR can occur after ischemic and hemorrhagic stroke. Infection, hypotension, hyponatremia, insomnia or stress, and benzodiazepine use are important triggers. New neurologic deficits are usually mild to moderate in severity and do not exceed the previous stroke deficits. Symptoms can start abruptly but can be remedied completely within hours or days after the resolution of the trigger (eg, treatment of an underlying infection). There does not appear to be any age predilection. Women, African American individuals, and those of other race/ethnicity are more frequently affected, possibly because of variances in neuronal susceptibility, disparities in health care resulting in more triggers such as infections, or other unmeasured confounders.
Our data show that nearly all types of focal stroke symptoms can recrudesce. The predominant face, arm, and leg involvement combined with the infrequent altered consciousness, gaze paresis, hemianopia, and extinction or inattention suggests that the long white matter tracts are more susceptible. This notion is supported by the frequent (79%) involvement of subcortical regions, the high prevalence of large strokes, and the significantly greater frequency of smallvessel disease that typically affects the motor sensory tracts. Despite the high frequency of large strokes and severe deficits, 116 patients (80.0%) achieved an mRS score lower than 3 but developed recrudescence, suggesting major recruitment of interhemispheric plasticity pathways during stroke recovery and, in turn, a limited reserve capacity for neurotransmission or a lower threshold for recrudescence. 9 Consistent with previous anecdotal reports and personal observations, toxic metabolic triggers were common. The iden- tified triggers can be classified into 3 groups, each with mechanistic implications: (1) fever and infection, (2) hypotension and hyponatremia, and (3) insomnia or stress and benzodiazepine use. Previous studies have shown that larger or more severe strokes confer greater susceptibility to infections [10] [11] [12] ; in rodents, a second immune challenge induces PSR. 3 It is conceivable that the large strokes in our recrudescence population increased the risk of acute infection, and subsequent infections resulted in recrudescence through cytokinemediated or other pathways. Similarly, sodium-water imbalances are well known to affect neuronal excitability and transmission along white matter tracts. 13 The association of PSR with insomnia and benzodiazepine use in our study and others 4 implicates neurotransmitter systems pertaining to γ-aminobutyric acid. Similar mechanisms have been implicated in other neurologic conditions associated with transient exacerbations, such as multiple sclerosis (Uhthoff phenomenon), migraine, and brain tumor. 7, 14 The implicated pathways may also explain the reversible stroke-like deficits observed in patients with severe glucose imbalances. 15 Given the diverse and systemic nature of these triggers and the fact that PSR involves a subset of prior stroke symptoms without new neurologic symptoms, the triggers likely act via subtle effects on the undamaged ipsilateral and contralateral brain regions that subserve poststroke plasticity. 16 Brain plasticity pathways are similarly implicated in patients with worsening poststroke deficits from subsequent ipsilateral strokes. 17, 18 A major strength of this study is the use of stringent diagnostic criteria that included DWI. These criteria require prospective validation and could be broadened to include asymptomatic prior stroke and the absence of new lesions on computed tomography of the head, which is far less sensitive but more widely available than DWI. These criteria were based on experience and consideration of features that would distinguish PSR from other conditions that can occur in chronic stroke ( Table 3) . Although DWI results are often normal in TIA, 19 DWI abnormality is associated with symptom duration, justifying the diagnostic criterion 4, which uses an arbitrary 1-hour symptom duration with negative DWI results to distinguish PSR from TIA or stroke. Ultimately, clinical acumen will be needed for diagnosis. The list of conditions in Table 3 is not comprehensive and omits stroke-like episodes associated with hypoglycemia, mitochondrial disorders, and rare conditions, such as retinal migraine and the syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (or HaNDL). In the PSR cohort, several triggers were identified on the basis of higher frequency in recrudescence when compared with adjacent non-PSR admissions. Similar retrospective crossover cohort studies have been successfully used to uncover stroke triggers and risk factors. 20, 21 We limited the recrudescence comparison to the first adjacent admission to minimize confounding from factors such as advancing age and changes in medications. These results have several management implications. Knowledge of the time course of resolution and the expected length of stay should improve resource use. It is important to prevent and promptly treat infections, hyponatremia, and other medical complications of stroke 22 and to avoid benzodiazepine use. A few patients received tissue plasminogen activator, emphasizing the importance of distinguishing acute stroke from recrudescence (Table 3) . However, none of the patients developed tissue plasminogen activator-related complications, the rate of which is known to be extremely low in stroke mimics, 23 supporting the view that tissue plasminogen activator should not be withheld in patients with acute stroke symptoms.
Limitations
The main limitation of this study is its retrospective nature, which relies on medical documentation for determining stroke severity and evolution. Because our RPDR search was restricted to the term recrudescence, we may not have captured all cases. However, capturing more cases of the same phenomenon using terms such as anamnesis or reactivation is unlikely to change study results. The proposed diagnostic criteria were designed to exclude mimics, but Todd paralysis and TIA or DWI-negative stroke still cannot be definitively excluded. Unblinded health record review may have led to an overestimation of subjective triggers, such as infection, although standard definitions were used as far as possible. The list of potential triggers was predefined; hence, there may be as-yet-unidentified factors leading to PSR. We did not perform multivariable analysis because of the relatively small number of cases and controls. The control group had at least 2 poststroke hospitalizations (1 with recrudescence) and may differ from patients with single PSR-related admissions, leading to a possible selection bias. We assessed adjacent admissions but not every readmission; thus, we cannot address whether triggers induce recrudescence at every exposure or require a certain threshold to induce symptom recurrence. These issues could be addressed in future studies.
Conclusions
The incidence or prevalence of PSR is not known but, on the basis of our observation, appears to be relatively frequent and more common with ischemic stroke than hemorrhagic stroke. To our knowledge, recognition of PSR remains sporadic. We envision that our diagnostic criteria and the results of this first attempt to characterize PSR will stimulate larger validation studies and ultimately enable prompt diagnosis and distinction from mimics in medical centers across the world. 
